ABSTRACT SUBMISSION GUIDELINES

1. General Information

Submission Deadline

- Submission is only available online at https://submission.summitmd.com/login.php?iid=58.
- Submission Deadline **EXTENDED**: **Friday, November 20, 2026**, 11:59 PM KST (UTC +9)

ID/Password for Submission

- To submit an abstract, you must join www.summitmd.com first. If you haven't signed up yet, please join summitMD before the submission.
- We recommend that you do NOT use a Hotmail account for your ID, as important notification emails such as acceptance letters and presentation guidelines may not be delivered properly.
- If you forget your password, click "Forgot Your Password?" on the login page.
- **Please be aware that DUPLICATE ABSTRACTS will not be allowed.**

2. Title

- The title of the abstract should be within 300 characters.
- It should be concise and specific, containing no abbreviations and indicating the nature of the investigation.
- Please make sure that **your title is capitalized in accordance with APA style**.
  Convert your title here to APA style and manually revise afterward.
  *ex) **A** **C**hallenging **C**ase **R**eport: Instant Coronary Intervention **in a** Female **Before** Kidney Transplant*

3. Author(s)

- The designation of both a first author and a presenter is required to complete a submission.
- First author, presenter, and co-author(s) can be the same person.
- **Country and Affiliation of abstract**: The country and affiliated institution of the abstract **MUST** be based on the institution and country where the study was conducted. Regardless of the submitter's or presenter's nationality, the abstract details (country and affiliation) must reflect the institution where the work was performed.
- Each author's information must be provided for submission.
- **Once you submit your abstract, a confirmation email will be sent to you (submitter). If your abstract is accepted, the designated presenter will receive further notification emails for the presentation. Make sure that all the contact information is correct.**

4. Category

- Abstract should involve the following disciplines in cardiovascular medicine and intervention.
- Select one category that is the closest to the subject of your abstract.
- If the category does not match the subject of the abstract, you may receive a low score from the reviewers.

CORONARY
ACS/AMI
Complex PCI
· *Left Main*
· *Bifurcation*
· *CTO*
· *Calcified Lesion*
· *Multi-Vessel Disease*
· *In-Stent Restenosis*
· *Long Lesion*
· *Small Vessel Disease*
· *Tandem Lesion*
Imaging & Physiology
· *Intracoronary Physiology (FFR, iFR, QFR, etc.)*
· *Invasive Imaging (IVUS, OCT, NIRS, VH, etc.)*
· *Non-Invasive Imaging (CTA, MRI, Echo, etc.)*
· *Angiography/QCA*
High-Risk Intervention (Diabetes, Heart Failure, Renal Failure, Shock, etc.)

Vascular Access and Closure
Adjunctive Procedures (Thrombectomy, Atherectomy, Special Balloons)
Complication Management
DES/BRS Technology
Drug-Coated Balloons
Hemodynamic Support
Pharmacotherapy
Surgical Therapy
Clinical Trials & Science
Cardiac Arrest and Cardiogenic Shock
Coronary Surgery and Hybrid Intervention
Vulnerable Plaque

STRUCTURAL

Aortic Valve Intervention
- *Complex TAVR*
- *Bicuspid AV*
- *Valve-in-Valve TAVR*
- *Coronary Artery Protection / Access*
- *Minimalist TAVR*
- *Non-femoral TAVR*
- *Antithrombotics*
- *Leaflet Modification*

Mitral Valve Intervention
- *TEER*
- *Transcatheter MV Replacement*
- *LVOT Obstruction and Leaflet Modification*
- *Mitral Stenosis and Balloon Valvuloplasty*
- *Paravalvular Leak Management*
- *ViV and ViR Intervention*

Tricuspid Valve Intervention
Imaging
- *Computed Tomography*
- *Echocardiography*

Pulmonic Valve Intervention
LAAO
Surgical Therapy
Complication Management
Other Structural Interventions

ENDOVASCULAR

Iliac / SFA Intervention
Stroke and Neurovascular Interventions
Thoracic & Abdominal Aortic Interventions
Venous Disease Intervention
Carotid Intervention
Thrombus Removal Devices and Techniques
Surgical Therapy
Other Endovascular Interventions

HEART FAILURE

Vascular Heart Disease and Cardiomyopathies
Cardiogenic Shock
Mechanical Circulatory Support
Pharmacotherapy
Surgical Therapy

INNOVATION

Digital Health and Artificial Intelligence
Technology Trends in Coronary Intervention
Technology Trends in Valve Intervention
Pharmacotherapy
Surgical Therapy

5. Content

Basic Info / Requirements

- Abstract must be submitted in English.
- Abstract consists of 4 sections: Background, Method, Result, and Conclusions
- Each section is required to contain min 150 char / max 2200 char (approx. 300-350 words). / images optional (up to 3 files)

Checklist

- You can copy and paste an existing Excel table or create a new table using the provided system tools; however, be sure to check again whether the special characters or symbols are not broken.
- Do **NOT** include the patient's personal information, such as name, identifier number, or date of birth. (Age and sex are allowed)
- Spaces are included in the character count.
- Use zeros before decimal points (e.g., 0.05, not .05).
- Use decimal points, not commas (e.g., 0.05, not 0,05).
- Use lowercase "p" values (e.g., $p < 0.05$).
- Provide a manufacturer name and location in parentheses for all brands or trade names.
- Never use the underline feature to denote the following symbols: ±, ≤, ≥
- Use space between numbers and symbols (e.g., 3 ± 4, not 3±4; 3 mg, not 3mg).
- All measurements must include a unit of measure. (e.g., systolic blood pressure "140 mmHg", not just "140").
- For brand-name drugs, include generic names in parentheses.
- Do not include references, credits, or grant support.
- The content of the submitted abstract is entirely the responsibility of the author(s).
- Duplicate submissions are strictly prohibited. Abstracts with identical or substantially similar content submitted under different author names will be excluded from review.

6. Review

- All submitted abstracts will be thoroughly evaluated by official reviewers.
- The result will influence the allocation to two different types of sessions – *Best Clinical Trials Session* and *Moderated Abstract Competition Session.*

7. Acceptance Notification

- The presenters of the accepted abstracts will be notified **at the end of January 2027**.
- The presenters will be informed of their presentation date and time with specific guidelines for the session.

8. Presentation

- Accepted abstracts will be allocated to *1) Best Clinical Trials From Abstracts, 2) Moderated Abstract Competition,* or *3) E-Poster Presentation (Online Only for those who are not available to attend, not a real-time presentation)* based on the scores assigned by official reviewers.

※ ***For every type of presentation, a presenter is required to submit the presentation slides.***

Session Type

1) Best Clinical Trials From Abstracts

- Abstracts containing novel findings that may improve current practices will be presented at this session.
- Studies that have been published before will be excluded from the review process.
- All the presenters in the Best Clinical Trials session will get a cash prize.
- Abstracts from this session will be featured in *TCTAP's Daily News.*

2) Moderated Abstract Competition

- This competition session will be led by prestigious moderators and panelists.
- The best presenter who gets the highest score from the moderators and panelists will get a cash prize and a Certificate.

3) E-Poster Presentation *(Online PPT Presentation via E-Science Station)*

- E-Poster Presentation is an online PPT presentation format, not a live presentation.
- **ALL presenters should submit their presentation files regardless of their attendance.** If a presenter won't present their abstract on-site, only the PPT presentation file will be posted as an E-Poster to the E-Science Station on the TCTAP website and at the conference venue.

- The uploaded materials will also remain accessible on the TCTAP E-Science Station and the SummitMD website.
- Please note that if the E-Poster Presentation file is not submitted by the specified deadline, it will not be uploaded to the website.

*** Benefits for Abstract Presenters:**

For High-Scoring Presenters ONLY

- Cash Prize for the Presenters in the Best Clinical Trials From Abstracts session
- Award for the Best Presenter in the Moderated Abstract Competition session

For ALL Presenters

- Free registration for TCTAP 2027
- Publication on the TCTAP E-Science Station and the SummitMD website

  ***As of TCTAP 2026, online publication in JACC will no longer be offered.** Accepted papers will instead be featured on TCTAP's own platforms to ensure timely dissemination and broadened reach across the international community.*
- An advantage in applying for the TCTAP Best Young Scientist Award

9. Withdrawal

- Before the submission deadline, you may log in and withdraw your submission at any time.
- After the deadline, please email us at submission@summitmd.com with your submission number and title to request a withdrawal.
- After acceptance notification, a withdrawal request must be made by Monday, February 28, 2027.

10. No-Show Policy

When you cannot attend the session to present your abstract, please notify the secretariat in advance via email at submission@summitmd.com. If the presenter fails to show up or sends a replacement without any notification, it may affect the acceptance of the Call for Science at future conferences.

11. Copyright Information

When abstracts are submitted, we assume that the author(s) grant copyright to the Congress Organization for publication on the websites www.summit-tctap.com and www.summitmd.com.

12. Assistance

If you need help with your submission, please contact us at +82-2-3010-7251 or submission@summitmd.com.